Gastrointestinal stromal tumor (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, and are commonly located in the stomach and small intestine. All GIST have malignant potential, ranging from small lesions with a benign behavior to highly malignant sarcomas. The prognosis of gastrointestinal stromal tumor is closely related to the tumor location、tumor size、mitotic count and rupture of the tumors. Adjuvant therapy with imatinib has significantly prolonged the survival time of GIST patients. Recently, more and more attention has been paid to the concept of individualized treatment for gastrointestinal stromal tumor. And this article reviews the strategy of individualized treatment for gastrointestinal stromal tumor.